Scarica l'app Stockscreener
4.25
0.71%
0.03
Dopo l'orario di chiusura:
4.27
0.02
+0.47%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMEA Giù?
Forum
Previsione
Biomea Fusion Inc Borsa (BMEA) Ultime notizie
Barclays PLC Purchases 24,162 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
HC Wainwright Reaffirms Buy Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Biomea Fusion to Become a Diabetes & Obesity Medicines Company - GlobeNewswire
Biomea Fusion Pivots to Diabetes Focus After Breakthrough Drug Shows 1.5% HbA1c Reduction - StockTitan
Biomea Fusion (NASDAQ:BMEA) Earns “Buy” Rating from D. Boral Capital - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Average Rating of “Buy” from Analysts - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Buy" by Analysts - MarketBeat
Biomea Fusion's (BMEA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Recent uptick might appease Biomea Fusion, Inc. (NASDAQ:BMEA) institutional owners after losing 75% over the past year - Simply Wall St
BMEABiomea Fusion, Inc. Latest Stock News & Market Updates - StockTitan
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study - GlobeNewswire
Biomea's Icovamenib Boosts Semaglutide Effects: 11.5% Extra Weight Loss, 43% More Muscle Mass - StockTitan
10 Best Diabetes Stocks To Buy Under $10 - Insider Monkey
Here’s Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10 - Insider Monkey
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Biomea Fusion CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Geode Capital Management LLC Raises Holdings in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Barclays PLC Increases Stock Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Short Interest Update - Defense World
State Street Corp Decreases Stock Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion (BMEA) – Analysts’ Weekly Ratings Changes - Defense World
Biomea Fusion Advances Diabetes Treatment with Positive Study Results - TipRanks
Biomea Fusion's SWOT analysis: clinical hold casts shadow on diabetes drug stock - Investing.com
Biomea Fusion shares hold with Buy rating after trial success By Investing.com - Investing.com Australia
Biomea Fusion shares hold with Buy rating after trial success - Investing.com
Biomea stock sinks 16% after Phase 2 data release - MSN
Biomea Fusion's (BMEA) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes - The Manila Times
Biomea Fusion Announces Positive Topline Results from - GlobeNewswire
Biomea Fusion's Diabetes Drug Shows Breakthrough Results in Phase II Trial, Achieves Key HbA1c Reductions - StockTitan
The Manufacturers Life Insurance Company Takes Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Analysts Set Biomea Fusion, Inc. (NASDAQ:BMEA) Target Price at $39.36 - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Rating of “Buy” by Analysts - Defense World
Biomea Fusion (NASDAQ:BMEA) Receives Buy Rating from HC Wainwright - Defense World
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) - The Manila Times
Biomea Fusion to Host Conference Call to Announce Topline - GlobeNewswire
Biomea Fusion to Unveil Key Phase II Diabetes Trial Results: COVALENT-111 Data Release Set for December - StockTitan
Biomea Fusion (NASDAQ:BMEA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Biomea Fusion's SWOT analysis: stock faces challenges amid clinical hold By Investing.com - Investing.com South Africa
Charles Schwab Investment Management Inc. Grows Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion's SWOT analysis: stock faces challenges amid clinical hold - Investing.com
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - The Manila Times
Biomea Fusion Announces Oral and Poster Presentations of - GlobeNewswire
Biomea Fusion Unveils Breakthrough Preclinical Data: Menin Inhibitor Boosts GLP-1 Therapy Effectiveness - StockTitan
HC Wainwright Reaffirms “Buy” Rating for Biomea Fusion (NASDAQ:BMEA) - Defense World
HC Wainwright Reaffirms "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia - The Manila Times
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):